ArticleJournal of experimental pharmacology2025
Effects of
Article in Journal of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhabdomyolysis (RML) is a complex disorder caused by muscle cell injury and the subsequent release of intracellular components into circulation. Statins are widely used and generally well tolerated; however, some patients report muscle weakness, particularly in the lower extremities. The concomitant use of statins with other substances, including herbal products such as khat ( Aim: This study aimed to evaluate the effects of khat extract on atorvastatin-induced rhabdomyolysis in rats. Methods: Methanolic extraction of khat leaves was performed, and phytochemical analysis confirmed the presence of alkaloids, tannins, flavonoids, and other bioactive compounds. Twenty-four healthy rats were randomly divided into four groups: control, khat extract (500 mg/kg), atorvastatin (40 mg/kg), and khat extract plus atorvastatin. Treatments were administered orally for 28 days. On day 28, blood samples were collected for biochemical assays of myoglobin, creatine kinase (CK-MM), lactate dehydrogenase (LDH, LDH5), alkaline phosphatase (ALP), troponin fast skeletal (fsTnI), creatinine, albumin, and total protein. Histopathological analysis of skeletal muscle and kidney tissues was also conducted. Data were analyzed using the Kruskal-Wallis, expression by median(IQR), CI(95%) with significance set at p < 0.05. Results: The khat-atorvastatin group showed significant weight reduction and marked increases in biochemical markers compared with controls. The khat-only and atorvastatin-only groups also demonstrated elevated biomarkers but at lower levels. Histopathology confirmed severe muscle necrosis and kidney tubular injury in the khat-atorvastatin group, while mild myopathy was evident in the khat-only and atorvastatin-only groups. Conclusion: Khat extract contributes to biochemical and histopathological changes indicative of muscle injury. When combined with atorvastatin, these effects are exacerbated, leading to pronounced myopathy and kidney damage. These findings suggest that khat use may potentiate statin-induced rhabdomyolysis and increase the risk of musculoskeletal and renal complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.